- Home
- EJH vs CANF Comparison
EJH vs CANF Comparison
Compare EJH & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EJH
- CANF
- Stock Information
- Founded
- EJH 2018
- CANF 1994
- Country
- EJH China
- CANF Israel
- Employees
- EJH N/A
- CANF N/A
- Industry
- EJH Other Consumer Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- EJH Consumer Discretionary
- CANF Health Care
- Exchange
- EJH Nasdaq
- CANF Nasdaq
- Market Cap
- EJH 8.2M
- CANF 9.4M
- IPO Year
- EJH 2021
- CANF N/A
- Fundamental
- Price
- EJH $0.66
- CANF $1.55
- Analyst Decision
- EJH
- CANF Strong Buy
- Analyst Count
- EJH 0
- CANF 2
- Target Price
- EJH N/A
- CANF $14.00
- AVG Volume (30 Days)
- EJH 2.1M
- CANF 138.1K
- Earning Date
- EJH 10-29-2024
- CANF 02-03-2025
- Dividend Yield
- EJH N/A
- CANF N/A
- EPS Growth
- EJH N/A
- CANF N/A
- EPS
- EJH N/A
- CANF N/A
- Revenue
- EJH $50,685,314.00
- CANF $667,000.00
- Revenue This Year
- EJH N/A
- CANF $409.56
- Revenue Next Year
- EJH N/A
- CANF N/A
- P/E Ratio
- EJH N/A
- CANF N/A
- Revenue Growth
- EJH N/A
- CANF N/A
- 52 Week Low
- EJH $0.54
- CANF $1.29
- 52 Week High
- EJH $36.70
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- EJH 46.27
- CANF 43.14
- Support Level
- EJH $0.59
- CANF $1.55
- Resistance Level
- EJH $0.65
- CANF $1.64
- Average True Range (ATR)
- EJH 0.11
- CANF 0.10
- MACD
- EJH -0.01
- CANF 0.01
- Stochastic Oscillator
- EJH 25.77
- CANF 17.14
About EJH E-Home Household Service Holdings Limited
E-Home Household Service Holdings Ltd is a household service company providing integrated household services through its website and WeChat platform across China. The company offers services including home appliance and housekeeping services. It operates its business mainly by receiving the orders online and providing the services offline. Its operations are organized into five reportable segments: installation and maintenance services, housekeeping services, senior care services, sales of pharmaceutical products and educational consulting services. The group's principal source of revenue comes from the Installation and Maintenance segment, followed by Housekeeping and Senior care services segment.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).